Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GridAI Technologies Corp.AZRX · Entity 7534 | Director · CHIEF FINANCIAL OFFICER | December 28, 2018 | January 02, 2019 |
| RELMADA THERAPEUTICS, INC.RLMD · Entity 5498 | Chief Financial Officer | September 09, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GridAI Technologies Corp.
Report date December 28, 2018 · Filed January 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,500 |
Reported balance
After 2018-12-28 transaction · row 1
1 source rowRow 1 · 2018-12-28 · Purchase · Acquired 20,000 · Balance 62,500 |
RELMADA THERAPEUTICS, INC.
Report date September 09, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000,000 |
Ending reported balance
After 2026-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-09 · Purchase · Acquired 120,200 · Balance 920,200 F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. F2: Purchase prices range from $4.16 to $4.20 per share, inclusive. Row 2 · 2026-09-10 · Purchase · Acquired 79,800 · Balance 1,000,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
F2: Purchase prices range from $4.16 to $4.20 per share, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2021 Filed Jan 26, 2021 19:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 607 | $35.16 | $21,342.12 |
DisclosureSEC source: 0001213900-21-004478 · ownership.xml · nonDerivative · entry 5 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F6 · price: Sales prices range from $35.00 to $35.61 per share, inclusive. Read SEC document |
| January 25, 2021 Filed Jan 26, 2021 19:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,280 | $35.27 | $45,145.60 |
DisclosureSEC source: 0001213900-21-004478 · ownership.xml · nonDerivative · entry 4 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,835 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F5 · price: Sales prices range from $35.00 to $35.51 per share, inclusive. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 19:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionOptions to purchase common stock · Derivative | 4,000 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001213900-21-004478 · ownership.xml · derivative · entry 6 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,250 Underlying: Common Stock · 4,000 shares Expires 2027-10-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · price: Not applicable F7 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four year period. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 19:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 409 | $36.15 | $14,785.35 |
DisclosureSEC source: 0001213900-21-004478 · ownership.xml · nonDerivative · entry 3 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,115 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F4 · price: Sales prices range from $36.06 to $36.37 per share, inclusive. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 19:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | SaleCommon Stock | 1,704 | $35.41 | $60,338.64 |
DisclosureSEC source: 0001213900-21-004478 · ownership.xml · nonDerivative · entry 2 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,524 F1 · kind: The sales reported on this Form 4 were effectuated pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 22, 2020. F2 · shares: The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range. F3 · price: Sales prices range from $35.04 to $35.98 per share, inclusive. Read SEC document |
| January 22, 2021 Filed Jan 26, 2021 19:28 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 4,000 | $324.00 | $1,296,000.00 |
DisclosureSEC source: 0001213900-21-004478 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 22, 2021 Filed Jan 27, 2021 07:46 UTC Amendment | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | Exercise / conversionCommon Stock | 4,000 | $3.24 | $12,960.00 |
DisclosureSEC source: 0001213900-21-004515 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 127,500 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-21-001419 · ownership.xml · derivative · entry 2 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Underlying: Common Stock · 127,500 shares Expires 2031-01-07 F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period. F2 · derivative.exercise_date: The options vest 25% one year from the date of grant, and thereafter in equal quarterly increments of 6.25% over the following three years. The options are subject to forfeiture upon failure by the Issuer to reach certain corporate objectives in 2021. Read SEC document |
| January 07, 2021 Filed Jan 11, 2021 16:07 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 127,500 | $0.00 Strike: $33.43 | $0.00 |
DisclosureSEC source: 0001213900-21-001419 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Underlying: Common Stock · 127,500 shares Expires 2031-01-07 F1 · derivative.exercise_date: The options vest from the date of grant in equal quarterly increments of 6.25% over a four-year period. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 16:51 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 120,000 | $43.47 Strike: $43.47 | $5,216,400.00 |
DisclosureSEC source: 0001213900-19-026848 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| October 21, 2019 Filed Oct 21, 2019 16:23 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | PurchaseCommon Stock | 978 | $23.00 | $22,494.00 |
DisclosureSEC source: 0001213900-19-020722 · ownership.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,228 Read SEC document |
| July 29, 2019 Filed Jul 30, 2019 17:09 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 500,000 | $2.20 Strike: $2.20 | $1,100,000.00 |
DisclosureSEC source: 0001213900-19-014043 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-07-29 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 18:44 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | PurchaseCommon Stock | 20,000 | $1.31 | $26,214.00 |
DisclosureSEC source: 0001415889-19-000015 · form4-01022019_030120.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · Director · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Read SEC document |
| December 20, 2018 Filed Dec 20, 2018 16:55 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 450,000 | $1.15 Strike: $1.15 | $517,500.00 |
DisclosureSEC source: 0001213900-18-017635 · ownership.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2028-12-20 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| July 12, 2018 Filed Jul 16, 2018 19:20 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantOptions · Derivative | 100,000 | $0.00 Strike: $3.04 | $0.00 |
DisclosureSEC source: 0001415889-18-001118 · form4-07162018_040700.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Director · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2023-06-28 F1 · derivative.exercise_date: Options with respect to 50,000 shares vest upon the acceptance of a U.S. IND for MS 1819, and the remaining 50,000 shares vest upon the the first CF patient doses with MS1819 anywhere in the globe. Read SEC document |
| October 20, 2017 Filed Oct 23, 2017 16:40 UTC | RELMADA THERAPEUTICS, INC. RLMD · Entity 5498 | GrantOptions to purchase common stock · Derivative | 425,000 | $0.81 Strike: $0.81 | $344,250.00 |
DisclosureSEC source: 0001213900-17-010835 · f4101917shenouda_relmada.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2027-10-20 F1 · derivative.exercise_date: Pursuant to the terms of the company's 2014 Stock Option and Equity Incentive Plan, 6.25% of the options shall vest each quarter from the date of grant. Read SEC document |
| October 19, 2017 Filed Oct 23, 2017 17:43 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantCommon Stock | 22,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-17-001684 · form4-10232017_021051.xml · nonDerivative · entry 1 Shenouda Maged · CIK 0001658369 · Director · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 F1 · price: Shares issued in connection with the Reporting Person's service on the Issuer's Board of Directors for the quarters ending March 31, 2017, June 30, 2017, and September 30, 2017. Read SEC document |
| September 25, 2017 Filed Sep 27, 2017 21:12 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantOptions · Derivative | 100,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0001415889-17-001573 · form4-09272017_060908.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Director · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-09-25 F1 · derivative.exercise_date: Options with respect to 75,000 shares vest upon the acceptance of a US IND for MS 1819, and the remaining 25,000 vest upon the Registrant's completion of a Phase IIa clinical trial for MS1819. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 16:39 UTC | GridAI Technologies Corp. AZRX · Entity 7534 | GrantOptions · Derivative | 30,000 | $0.00 Strike: $4.48 | $0.00 |
DisclosureSEC source: 0001415889-17-000212 · form4-02072017_010233.xml · derivative · entry 1 Shenouda Maged · CIK 0001658369 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-02-03 F1 · derivative.exercise_date: 10,000 options vest immediately. The balance vests 1/24 per month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.